| Dermatology Of New Mexico Llc | |
|
610 Broadway Blvd Ne Albuquerque NM 87102-2372 | |
| (505) 225-2500 | |
| (505) 225-2025 |
| Full Name | Dermatology Of New Mexico Llc |
|---|---|
| Speciality | Clinic/Center |
| Location | 610 Broadway Blvd Ne, Albuquerque, New Mexico |
| Authorized Official Name and Position | Suraj2252500 Reddy (CEO / MD) |
| Authorized Official Contact | 5052252500 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Dermatology Of New Mexico Llc 610 Broadway Blvd Ne Albuquerque NM 87102-2372 Ph: (505) 225-2500 | Dermatology Of New Mexico Llc 610 Broadway Blvd Ne Albuquerque NM 87102-2372 Ph: (505) 225-2500 |
| NPI Number | 1104468438 |
|---|---|
| Provider Enumeration Date | 10/08/2019 |
| Last Update Date | 10/08/2019 |
| Medicare PECOS PAC ID | 6608209606 |
|---|---|
| Medicare Enrollment ID | O20191205001106 |
News Archive
People who feel powerful are more likely to believe they can beat cancer if it's described in human terms, according to new study in the Journal of Consumer Research.
A WHO report released Wednesday says countries with the highest drug-resistant tuberculosis burdens are making progress in addressing the disease, "but despite the recent scale up in efforts, the world needs to do much more to get care to all [multi-drug resistant] patients who need it," WHO Director-General Margaret Chan said, Times LIVE reports.
A potential mechanism to combat diseases caused by haemorrhagic fever viruses has been discovered by researchers at the University of Montreal's Department of Biochemistry and Molecular Medicine. These diseases present a dramatic risk to human health as they often spread quickly and kill a high percentage of infected individuals, as demonstrated by the recent Ebola outbreaks.
Ironwood Pharmaceuticals, Inc. today announced that the underwriters of its February 2, 2010 initial public offering (IPO) have exercised their over-allotment option in full on an additional 2.5 million shares of Ironwood's Class A common stock. With the completion of the IPO and the exercise of the over-allotment option, Ironwood has approximately 97.4 million shares of common stock outstanding (approximately 19.2 million shares of Class A common stock and 78.2 million shares of Class B common stock).
An oral targeted therapy gentle enough to be used by patients in their 70s or 80s is showing benefit in treating high-risk myelodysplastic syndrome (MDS), a pre-leukemic disorder that can progress to acute myelogenous leukemia (AML), according to a study presented at the annual meeting of the American Society of Hematology (ASH).
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104468438 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261Q00000X | Clinic/center | (* (Not Available)) | Primary |
| Provider Name | Suraj G Reddy |
|---|---|
| Provider Type | Practitioner - Dermatology |
| Provider Identifiers | NPI Number: 1740485275 PECOS PAC ID: 3577623941 Enrollment ID: I20081117000084 |
News Archive
People who feel powerful are more likely to believe they can beat cancer if it's described in human terms, according to new study in the Journal of Consumer Research.
A WHO report released Wednesday says countries with the highest drug-resistant tuberculosis burdens are making progress in addressing the disease, "but despite the recent scale up in efforts, the world needs to do much more to get care to all [multi-drug resistant] patients who need it," WHO Director-General Margaret Chan said, Times LIVE reports.
A potential mechanism to combat diseases caused by haemorrhagic fever viruses has been discovered by researchers at the University of Montreal's Department of Biochemistry and Molecular Medicine. These diseases present a dramatic risk to human health as they often spread quickly and kill a high percentage of infected individuals, as demonstrated by the recent Ebola outbreaks.
Ironwood Pharmaceuticals, Inc. today announced that the underwriters of its February 2, 2010 initial public offering (IPO) have exercised their over-allotment option in full on an additional 2.5 million shares of Ironwood's Class A common stock. With the completion of the IPO and the exercise of the over-allotment option, Ironwood has approximately 97.4 million shares of common stock outstanding (approximately 19.2 million shares of Class A common stock and 78.2 million shares of Class B common stock).
An oral targeted therapy gentle enough to be used by patients in their 70s or 80s is showing benefit in treating high-risk myelodysplastic syndrome (MDS), a pre-leukemic disorder that can progress to acute myelogenous leukemia (AML), according to a study presented at the annual meeting of the American Society of Hematology (ASH).
› Verified 3 days ago
| Provider Name | Shilpa G Reddy |
|---|---|
| Provider Type | Practitioner - Dermatology |
| Provider Identifiers | NPI Number: 1639218639 PECOS PAC ID: 1850583485 Enrollment ID: I20101014000223 |
News Archive
People who feel powerful are more likely to believe they can beat cancer if it's described in human terms, according to new study in the Journal of Consumer Research.
A WHO report released Wednesday says countries with the highest drug-resistant tuberculosis burdens are making progress in addressing the disease, "but despite the recent scale up in efforts, the world needs to do much more to get care to all [multi-drug resistant] patients who need it," WHO Director-General Margaret Chan said, Times LIVE reports.
A potential mechanism to combat diseases caused by haemorrhagic fever viruses has been discovered by researchers at the University of Montreal's Department of Biochemistry and Molecular Medicine. These diseases present a dramatic risk to human health as they often spread quickly and kill a high percentage of infected individuals, as demonstrated by the recent Ebola outbreaks.
Ironwood Pharmaceuticals, Inc. today announced that the underwriters of its February 2, 2010 initial public offering (IPO) have exercised their over-allotment option in full on an additional 2.5 million shares of Ironwood's Class A common stock. With the completion of the IPO and the exercise of the over-allotment option, Ironwood has approximately 97.4 million shares of common stock outstanding (approximately 19.2 million shares of Class A common stock and 78.2 million shares of Class B common stock).
An oral targeted therapy gentle enough to be used by patients in their 70s or 80s is showing benefit in treating high-risk myelodysplastic syndrome (MDS), a pre-leukemic disorder that can progress to acute myelogenous leukemia (AML), according to a study presented at the annual meeting of the American Society of Hematology (ASH).
› Verified 3 days ago
News Archive
People who feel powerful are more likely to believe they can beat cancer if it's described in human terms, according to new study in the Journal of Consumer Research.
A WHO report released Wednesday says countries with the highest drug-resistant tuberculosis burdens are making progress in addressing the disease, "but despite the recent scale up in efforts, the world needs to do much more to get care to all [multi-drug resistant] patients who need it," WHO Director-General Margaret Chan said, Times LIVE reports.
A potential mechanism to combat diseases caused by haemorrhagic fever viruses has been discovered by researchers at the University of Montreal's Department of Biochemistry and Molecular Medicine. These diseases present a dramatic risk to human health as they often spread quickly and kill a high percentage of infected individuals, as demonstrated by the recent Ebola outbreaks.
Ironwood Pharmaceuticals, Inc. today announced that the underwriters of its February 2, 2010 initial public offering (IPO) have exercised their over-allotment option in full on an additional 2.5 million shares of Ironwood's Class A common stock. With the completion of the IPO and the exercise of the over-allotment option, Ironwood has approximately 97.4 million shares of common stock outstanding (approximately 19.2 million shares of Class A common stock and 78.2 million shares of Class B common stock).
An oral targeted therapy gentle enough to be used by patients in their 70s or 80s is showing benefit in treating high-risk myelodysplastic syndrome (MDS), a pre-leukemic disorder that can progress to acute myelogenous leukemia (AML), according to a study presented at the annual meeting of the American Society of Hematology (ASH).
› Verified 3 days ago
Double Happiness Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 4104 Ponderosa Ave Ne, Albuquerque, NM 87110 Phone: 505-385-4127 Fax: 505-265-5041 | |
Albuquerque Internal Medicine Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 4121 Montgomery Blvd Ne, Albuquerque, NM 87109 Phone: 505-314-0748 | |
Gabriella Good Md Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3015 Indian Farm Ln Nw, Albuquerque, NM 87107 Phone: 505-259-8694 Fax: 186-660-7177 | |
Hands On Health Care, P.c. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3825 Eubank Blvd Ne Ste C, Albuquerque, NM 87111 Phone: 505-298-8020 | |
Medicus Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 10401 Montgomery Pkwy Ne, Albuquerque, NM 87111 Phone: 505-234-1040 Fax: 505-293-7183 | |
New Mexico Neuromuscular Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2741 Indian School Rd Ne, Albuquerque, NM 87106 Phone: 505-255-8682 Fax: 505-255-7890 | |
Lovelace Healthcare Center-rio Bravo Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 200 Rio Bravo Blvd Se, Albuquerque, NM 87105 Phone: 505-873-6400 Fax: 505-873-6403 |